Cassava Sciences Inc. (NASDAQ: SAVA) announced the publication of results from two phase 3 clinical trials of simufilam for Alzheimer's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE